ロード中...
Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept
Epidemiological studies indicate that diabetes is the second most common comorbidity in COVID-19 (coronavirus disease 2019). Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, exerts direct cardioprotective and nephroprotective effects. DARE-19 (Dapagliflozin in Respiratory Failure in Patie...
保存先:
| 出版年: | J Cardiovasc Pharmacol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Journal of Cardiovascular Pharmacology
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8253377/ https://ncbi.nlm.nih.gov/pubmed/34001719 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FJC.0000000000001011 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|